- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. - Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts - Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact. - Price entering the gap from that day's drop. - Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued. - Bull flagging right under the gap.
Play: Bullish Gap Fill Buy the Dip under the key level to scale in Use $232.41 as inflection point. Look for breakout with increased volume Price Target: 270 Under $224 will invalidate